Facebook
X
LinkedIn
Forward
Global Perspectives in Urothelial Carcinoma (2025)
The 2025 Global Perspectives in Urothelial Carcinoma is an educational series focused on the latest advancements in Urothelial Carcinoma (UC) designed to meet the educational needs of our global audience. The series will consists of three live webinars presented in English with a focus on three different regions (German, LATAM and Japan). Each activity will include a US based moderator and panel of local faculty to the region, including urologists and a medical oncologist . This 90- minute live virtual activity will explore the evolving therapeutic options for patients with locally advanced (la) or metastatic urothelial carcinoma (mUC), discuss the value of early identification and management of adverse events associated with UC, and the importance of patient education. Local experts will discuss how AUA and local regional clinical guidelines translate into practice and the various roles played by the multidisciplinary team in the treatment advanced and metastatic urothelial carcinoma.
Presented in English, the activity is of value to the global urologic community.
This live virtual event will offer simultaneous translation in 50+ languages. Powered by an involved AI based technology Wordly, attendees will be able to access the audio and captioning translations in real time to help make the course more accessible to our colleagues around the globe.
The 2025 Global Perspectives in Urothelial Carcinoma series is presented by the AUA in partnership with the Japanese Urological Association (JUA), Sociedade Brasileira de Urologia (SBU), Confederación Americana de Urología (CAU) and Deutsche Gesellschaft für Urologie (DGU).
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- Astellas and Pfizer, Inc.
Target Audience
- Urologists
Learning Objectives
After participating in this CME activity, participants will be able to:
- Identify new and emerging treatment options in the locally advanced (la)/metastatic urothelial carcinoma (mUC) setting, including combination regimens and optimal sequencing.
- Analyze mechanisms of action of novel agents in the la/mUC setting.
- Address the roles of the urologist, medical oncologist, radiation oncologist, and other clinicians in delivering holistic, multidisciplinary care to UC patients.
- Incorporate AUA and relevant local/regional clinical guidelines updates for UC treatments into practice.
- Properly manage adverse events associated with therapies for la and mUC and discuss ways to improve early identification.
- Determine appropriate management strategies to reduce the incidence of AEs to minimize morbidity, including identifying methods to leverage multidisciplinary teams and advanced practice providers to achieve these goals.
Welcome
Pre-test
- Segment 1: New and Emerging Treatment Options & Mechanisms of Action of Novel Agents in the la/mUC Setting
- Segment 2: Delivering Holistic, Multidisciplinary Care to UC Patients
- Segment 3: Incorporating Guideline into Practice
- Segment 4: Managing Adverse Events for la and mUC Therapies
- Segment 5: Patient Education
Post-Test
Q&A Session